Beta-casein micelle assemblies for oral drug delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery systems face challenges with poor bioavailability due to poor absorption, stability, and solubility issues in the gastrointestinal tract, leading to discomfort and non-compliance in patients, especially for orally administered drugs.
Innovation Solution
Development of a dried composition comprising β-casein micelles and complexes that are stable in the dried state and retain biological activity upon re-suspension, allowing for effective delivery of therapeutic agents across mucosal membranes without the need for calcium ions, maintaining a high percentage of β-casein content and forming under specific pH conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral administration of drugs is used to improve patient compliance and avoid injection discomfort, then ease of operation is improved, but bioavailability deteriorates due to poor absorption, stability, and solubility in the gastrointestinal tract
Solution Approach 1:
The patent uses casein micelles as a composite delivery system that combines protein structures with drug molecules. The micelles are formed by self-assembly of casein proteins under specific pH conditions, creating a protective composite structure that encapsulates the drug and enables oral delivery while maintaining bioavailability through mucosal absorption
Solution Approach 2:
The patent exploits pH-dependent parameter changes to control micelle formation and drug delivery. Casein micelles form at neutral pH and can be disassembled in acidic environments, allowing controlled release. The system transitions between assembled and disassembled states based on pH, enabling protection in the stomach and release in the intestine or at mucosal surfaces
2Reliability
If biocompatible polymeric capsules or liposomes are used to protect drugs from degradation and facilitate transport, then reliability is improved, but device complexity increases
Solution Approach 1:
The casein micelles self-assemble under specific pH conditions without requiring complex manufacturing processes, external assembly equipment, or multiple processing steps. The proteins spontaneously organize into micellar structures that encapsulate the drug, eliminating the need for complex fabrication equipment and procedures while maintaining protective functionality
Solution Approach 2:
The patent extracts and utilizes the natural self-assembling properties of casein proteins, removing the need for complex synthetic polymer systems. By focusing on the inherent micelle-forming capability of casein under controlled pH conditions, the system simplifies the delivery mechanism while maintaining drug protection and delivery effectiveness
3Manufacturing precision
If casein micelles are re-assembled using calcium ions and high pressure as described in prior art, then manufacturing precision is improved, but device complexity and process complexity increase
Solution Approach 1:
The patent controls micelle assembly primarily through pH adjustments rather than requiring calcium ion addition or high-pressure processing. By changing the pH to neutral conditions, casein proteins naturally self-assemble into micelles, achieving precise control over assembly while avoiding complex equipment and multi-step processes
Solution Approach 2:
The patent removes the requirement for calcium ions and high-pressure equipment from the micelle assembly process. By relying solely on pH-controlled self-assembly of casein proteins, the system achieves micelle formation without additional chemicals or complex mechanical intervention, simplifying both the process and equipment requirements
4Reliability
If drugs are protected from acid digestion in the stomach, then reliability is improved, but loss of time occurs due to the need for additional protective mechanisms
Solution Approach 1:
The casein micelles are pre-formed with drug encapsulation before administration, providing immediate protection from gastric acid upon oral ingestion. The micellar structure is already in place to shield the drug, eliminating the need for additional protective mechanisms or sequential processing steps that would delay delivery
Solution Approach 2:
The micellar composite structure provides inherent acid protection through its protein composition and assembly architecture. The casein micelles naturally resist gastric acid digestion while maintaining drug integrity, offering protection without requiring additional protective coatings or multi-layer systems that would increase complexity and delivery time
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The β-casein micelle compositions provide stable and effective delivery of therapeutic agents, maintaining particle size, drug load, and biological activity over a wide pH and temperature range, enhancing bioavailability and patient compliance by protecting drugs from acidic environments and improving solubility and stability.
Implementation Method 1
The β-casein micelle compositions provide stable and effective delivery of therapeutic agents, maintaining particle size, drug load, and biological activity over a wide pH and temperature range, enhancing bioavailability and patient compliance by protecting drugs from acidic environments
Implementation Method 2
The caseins are held together in the micelles by hydrophobic interactions as well as by calcium-phosphate bridges
Implementation Method 3
The caseins are held together in the micelles by hydrophobic interactions as well as by calcium-phosphate bridges
Data Source
AI summary
The present invention discloses a dried composition comprising β-casein micelles, assemblies and complexes thereof. The dried composition is stable in the dried state as well as upon re-suspension The dried composition retains the biological activity, drug load capacity, particle size and particle size distribution of the β-casein micelles, assemblies and complexes comprising the active pharmaceutical ingredient, within the dried state and upon resuspension in a buffer or an aqueous pharmaceutical carrier.